The concept of treatment-free remission in chronic myeloid leukemia

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

(2016) A Hochhaus et al.   LEUKEMIA

Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study

(2015) Silvia Mori et al.   AMERICAN JOURNAL OF HEMATOLOGY

The interferon-alpha revival in CML

(2015) Moshe Talpaz et al.   ANNALS OF HEMATOLOGY

Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization

(2015) Nicholas C. P. Cross et al.   ANNALS OF HEMATOLOGY

Managing pregnancy in chronic myeloid leukaemia

(2015) Renuka Palani et al.   ANNALS OF HEMATOLOGY

Is there a best TKI for chronic phase CML?

(2015) R. A. Larson   BLOOD

Pediatric chronic myeloid leukemia is a unique disease that requires a different approach

(2015) N. Hijiya et al.   BLOOD

Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients

(2015) Giovanni Caocci et al.   EXPERIMENTAL HEMATOLOGY

High frequency of cryptic chromosomal rearrangements involving the LMO2 gene in T-cell acute lymphoblastic leukemia

(2015) L. Wu et al.   HAEMATOLOGICA

Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia

(2015) A Burchert et al.   LEUKEMIA

Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib

(2015) F Castagnetti et al.   LEUKEMIA

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

(2015) L Kalmanti et al.   LEUKEMIA

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

(2015) A Hochhaus et al.   LEUKEMIA

Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients

(2015) Joon Seong Park et al.   LEUKEMIA & LYMPHOMA

Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists

(2015) Stéphane Prost et al.   NATURE

High frequency of cryptic chromosomal rearrangements involving the LMO2 gene in T-cell acute lymphoblastic leukemia

(2015) L. Wu et al.   HAEMATOLOGICA

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

(2015) Jun Imagawa et al.   Lancet Haematology

Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms

(2014) D. Niebel et al.   BLOOD

Platelet 12-LOX is essential for Fc RIIa-mediated platelet activation

(2014) J. Yeung et al.   BLOOD

Do we need more drugs for chronic myeloid leukemia?

(2014) Tessa L. Holyoake et al.   IMMUNOLOGICAL REVIEWS

Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?

(2014) Johan Richter et al.   JOURNAL OF CLINICAL ONCOLOGY

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors

(2013) Lorenzo Falchi et al.   AMERICAN JOURNAL OF HEMATOLOGY

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Isolated plasmacytoma involving the brain parenchyma and cerebral spinal fluid

(2013) Q. Huang   BLOOD

Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML

(2013) S. Branford et al.   BLOOD

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

(2013)   BLOOD

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

(2013) D. M. Ross et al.   BLOOD

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

(2013) Rüdiger Hehlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

(2013) Philippe Rousselot et al.   JOURNAL OF CLINICAL ONCOLOGY

Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib

(2013) F Efficace et al.   LEUKEMIA

Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib

(2013) T D Kim et al.   LEUKEMIA

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

(2013) J.E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia

(2012) M. Horn et al.   BLOOD

Standardized definitions of molecular response in chronic myeloid leukemia

(2012) N C P Cross et al.   LEUKEMIA

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

(2011) F. Efficace et al.   BLOOD

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

(2011) A. Hamilton et al.   BLOOD

Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment

(2011) S. Chu et al.   BLOOD

Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease

(2011) J.-C. Chomel et al.   BLOOD

Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib

(2011) A. Kumari et al.   BLOOD

BCR-ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib Treatment

(2011) A. M. Stein et al.   CLINICAL CANCER RESEARCH

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia

(2011) N. Takahashi et al.   HAEMATOLOGICA

Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008

(2011) Magnus Björkholm et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

(2011) Carlo Gambacorti-Passerini et al.   JNCI-Journal of the National Cancer Institute

Curing CML with imatinib—a dream come true?

(2011) Michael Deininger   Nature Reviews Clinical Oncology

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

(2010) D M Ross et al.   LEUKEMIA

PR1-Specific T Cells Are Associated with Unmaintained Cytogenetic Remission of Chronic Myelogenous Leukemia After Interferon Withdrawal

(2010) Shreya Kanodia et al.   PLoS One

Standardisation of molecular monitoring for chronic myeloid leukaemia

(2009) Nicholas C.P. Cross   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Harmonization of molecular monitoring of CML therapy in Europe

(2009) M C Müller et al.   LEUKEMIA

Chronic myelogenous leukemia stem cells: What’s new?

(2009) Mhairi Copland   Current Hematologic Malignancy Reports